Investors Homology Medicines is focused on advancing our genetic medicines platform as one-time treatments and potential cures for patients with rare diseases Overview Stock Information Stock Quote & Chart Historical Price Lookup Stock Calculator News & Events News Releases Investor Calendar Presentations Financial Information SEC Filings Annual Reports Analyst Coverage Corporate Governance Governance Highlights Management Team Board of Directors Committee Composition Investor Resources Email Alerts Contact IR Homology Medicines is focused on advancing our genetic medicines platform as one-time treatments and potential cures for patients with rare diseases News Releases Year All20232022202120202019201820172016 Date Title May 16, 2023 Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting May 11, 2023 Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights May 03, 2023 Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting Mar 15, 2023 Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting Mar 09, 2023 Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights Mar 09, 2023 Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer Mar 02, 2023 Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference Feb 22, 2023 Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting Jan 04, 2023 Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs
Year All20232022202120202019201820172016 Date Title May 16, 2023 Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting May 11, 2023 Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights May 03, 2023 Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting Mar 15, 2023 Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting Mar 09, 2023 Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights Mar 09, 2023 Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer Mar 02, 2023 Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference Feb 22, 2023 Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting Jan 04, 2023 Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs